Biological material for biomarker research in spondyloarthritis: mapping the availability in European rheumatology registries

Dear Editor, Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are chronic inflammatory diseases involving peripheral and axial joints and entheses. They are characterized by chronic inflammation and progressive structural damage, which cause functional impairment and reduced quality of life. Research utilizing genetics and soluble biomarkers such as autoantibodies and cytokines, has the potential to provide insights into the pathophysiology and disease mechanisms as well as disease activity, treatment response and prognosis [1, 2]. Certain genetic and inflammatory markers have been associated with disease susceptibility and treatment response in SpA (e.g. HLA-B27 and CRP). Nevertheless, results are contradictory, and few targeted biomarkers are currently utilized in routine care management. This illustrates the need for further research in order to transition towards personalized health care.

International collaboration and data sharing enable larger sample sizes—enhancing the statistical power of biomarker studies. Furthermore, pooling of data from multiple centres with diverse patient populations increase external validity of the findings [3]. Biological material should be accompanied by corresponding clinical longitudinal data on demographics, disease manifestations and activity, and treatment efficacy and safety. This could be achieved by anchoring sampling for biomarker studies within established rheumatology registries that prospectively follow up large cohorts of patients in routine care settings.